Date: 2013-05-28
Type of information: Licensing agreement
Compound: protein therapeutics
Company: Thrombogenics (Belgium) Eleven Biotherapeutics (USA)
Therapeutic area: Ophtalmological diseases
Type agreement: licensing
Action mechanism: protein therapeutics
Disease: diabetic eye diseases such as diabetic macular edema
Details: * On May 28, 2013, ThromboGenics, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, has announced that it has commenced R&D of innovative protein therapeutics to address a novel ThromboGenics-identified biologic target implicated in a range of diabetic eye diseases such as diabetic macular edema (DME). ThromboGenics will utilize Eleven Biotherapeutics’ proprietary AMP-Rx protein design technology to create a novel therapeutic of ThromboGenics’ selection optimized for improved pharmaceutical characteristics and therapeutic benefits.
Financial terms: ThromboGenics will have the exclusive license to all future developments and commercialization of this novel protein. In exchange, Eleven Biotherapeutics will receive an undisclosed upfront payment, and is eligible to receive undisclosed development, regulatory and sales milestone payments as well as royalties on potential future sales commensurate with industry standards.
Latest news:
